Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 8;13(10):798.
doi: 10.3390/cells13100798.

Early Stage In Vitro Bioprofiling of Potential Low-Molecular-Weight Organoboron Compounds for Boron Neutron Capture Therapy (BNCT)-Proposal for a Guide

Zbigniew J Leśnikowski  1 , Filip Ekholm  2 , Narayan S Hosmane  3 , Martin Kellert  4 , Eiji Matsuura  5 , Hiroyuki Nakamura  6 , Agnieszka B Olejniczak  7 , Luigi Panza  4   8 , Louis M Rendina  9 , Wolfgang A G Sauerwein  4   10
Affiliations

Early Stage In Vitro Bioprofiling of Potential Low-Molecular-Weight Organoboron Compounds for Boron Neutron Capture Therapy (BNCT)-Proposal for a Guide

Zbigniew J Leśnikowski et al. Cells. .

Abstract

Given the renewed interest in boron neutron capture therapy (BNCT) and the intensified search for improved boron carriers, as well as the difficulties of coherently comparing the carriers described so far, it seems necessary to define a basic set of assays and standardized methods to be used in the early stages of boron carrier development in vitro. The selection of assays and corresponding methods is based on the practical experience of the authors and is certainly not exhaustive, but open to discussion. The proposed tests/characteristics: Solubility, lipophilicity, stability, cytotoxicity, and cellular uptake apply to both low molecular weight (up to 500 Da) and high molecular weight (5000 Da and more) boron carriers. However, the specific methods have been selected primarily for low molecular weight boron carriers; in the case of high molecular weight compounds, some of the methods may need to be adapted.

Keywords: BNCT; bioprofiling; boron carriers; drug development; in vitro methods; pre-clinical testing.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flow chart for in vitro bioprofiling of potential boron carriers for BNCT.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sauerwein W. Principles and roots of neutron capture therapy. In: Sauerwein W., Wittig A., Moss R., Nakagawa Y., editors. Neutron Capture Therapy. Principles and Applications. Springer; Berlin/Heidelberg, Germany: New York, NY, USA: Dordrecht, The Netherlands: London, UK: 2012. pp. 1–16. - DOI
    1. IAEA: Advances in Boron Neutron Capture Therapy. International Atomic Energy Agency; Vienna, Austria: 2023.
    1. Kumada H., Sakae T., Sakurai H. Current development status of accelerator-based neutron source for boron neutron capture therapy. EPJ Tech. Instrum. 2023;10:18. doi: 10.1140/epjti/s40485-023-00105-5. - DOI
    1. Safavi-Naeini M., Chacon A., Guatelli S., Franklin D.R., Bambery K., Gregoire M.-C., Rosenfeld A. Opportunistic dose amplifcation for proton and carbon ion therapy via capture of internally generated thermal neutrons. Sci. Rep. 2018;8:16257. doi: 10.1038/s41598-018-34643-w. - DOI - PMC - PubMed
    1. Howell N., Middleton R.J., Sierro F., Wyatt N.A., Chacon A., HFraser B.H., Bambery K., Livio E., Dobie C., Bevitt J.J., et al. Neutron capture enhances dose and reduces cancer cell viability in and out of beam during helium and carbon ion therapy. Int. J. Radiat. Oncol. Biol. Phys. 2024 doi: 10.1016/j.ijrobp.2024.02.052. accepted . - DOI - PubMed

Publication types

Substances

LinkOut - more resources